ReviewClinical medicine (London, England)2011
Pathogenesis and treatment of hepatic fibrosis: is cirrhosis reversible?
Review in Clinical medicine (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Fibrotic microRNAs in the suppression of HSC activation and ECM deposition to facilitate the regression of hepatic fibrosis in zebrafish.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Niacin Derivatives in MASLD: Metabolic and Therapeutic Insights.Nutrients · 2026Review
- Anti-Fibrotic Effect of Oleamide Identified from theInternational journal of molecular sciences · 2025Article
- Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular Crosstalk.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Dodecanedioic acid prevents and reverses metabolic-associated liver disease and obesity and ameliorates liver fibrosis in a rodent model of diet-induced obesity.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Aging, ROS, and cellular senescence: a trilogy in the progression of liver fibrosis.Biogerontology · 2024Review
- Enhanced In Vitro Efficacy of Verbascoside in Suppressing Hepatic Stellate Cell Activation via ROS Scavenging with Reverse Microemulsion.Antioxidants (Basel, Switzerland) · 2024Article
- Bariatric-induced microbiome changes alter MASLD development in association with changes in the innate immune system.Frontiers in microbiology · 2024Article
- miR-98-5p as a novel biomarker suppress liver fibrosis by targeting TGFβ receptor 1.Hepatology international · 2022Article
- Regression of portal hypertension: underlying mechanisms and therapeutic strategies.Hepatology international · 2021Review
- The therapeutic potential of induced hepatocyte-like cells generated by direct reprogramming on hepatic fibrosis.Stem cell research & therapy · 2019Article
- Liver function tests in identifying patients with liver disease.Clinical and experimental gastroenterology · 2018Article
- Quantitative analysis of real-time tissue elastography for evaluation of liver fibrosis.International journal of clinical and experimental medicine · 2014Article
- Oxymatrine liposome attenuates hepatic fibrosis via targeting hepatic stellate cells.World journal of gastroenterology · 2012Article
- UnearthingJournal of clinical and experimental hepatologyArticle
- Nuclear magnetic resonance evaluation of inflammatory activity from chronic viral Hepatitis B.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.